Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Rapid Initiation of ART

In this on-demand recording of a live webinar, expert faculty review key considerations for rapid initiation of ART. Topics include current recommendations and a discussion of the data to support ART options for rapid initiation.
Jason Halperin, MD, MPH
Jürgen K. Rockstroh, MD
Released: September 29, 2021

In this episode from the series “Key Decisions in HIV Care,” Jason Halperin, MD, MPH, and Jürgen K. Rockstroh, MD, discuss important considerations in the rapid initiation of ART, including guideline recommendations and data supporting recommended ART regimen options for rapid initiation and emerging data for the 2-drug regimen dolutegravir/lamivudine for rapid start from the STAT study. Following their dialogue, the faculty field questions from healthcare professionals.

Information on this Educational Activity

Faculty

Jason Halperin, MD, MPH

Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana

Jason Halperin, MD, MPH, has no relevant conflict of interest to report.
Jürgen K. Rockstroh, MD

Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Galapagos, Gilead Sciences, Merck, and ViiV and fees for non-CME/CE services from Gilead Sciences, Janssen, Merck, Theratechnologies, and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Dr Yan Zhao discusses data from IDWeek 2022 on long-term benefits of early vs delayed treatment initiation in people with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 22, 2022

Expert discussion of HIV Glasgow 2022 data on optimizing islatravir dosing based on lymphocyte changes and IDWeek 2022 data on LA CAB + RPV real-world effectiveness in the US OPERA Cohort, from Clinical Care Options (CCO)

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022

Clinical Care Options (CCO) downloadable slides from Drs Joseph Eron, Karine Lacombe, Chloe Orkin, and Babafemi Taiwo on HIV data from IDWeek and HIV Glasgow 2022

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings